Physician profile
Jim C Chen
NPI 1295846012
$1,660.82
in general payments reported to CMS, 2019-2025
11 companies · $202 in 2025
The $202 reported for 2025 was more than what a typical Geriatric Psychiatry provider received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $621 · 2020: $19.46 · 2021: $395 · 2022: $125 · 2023: $44.51 · 2024: $254 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $500.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $374.41 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $364.32 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Allergan, INC. | $314.96 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $136.19 | 2019 | |
| Neurocrine Biosciences, INC. | $128.53 | 2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $106.45 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $99.94 | 2025 | Caplyta |
| Alkermes, INC. | $44.51 | 2023 | Lybalvi |
| Beone Medicines USA, INC. | $40.11 | 2025 | Brukinsa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $31.01 | 2025 | Rejoyn |
| Abbvie INC. | $20.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jim Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.